Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade

被引:60
|
作者
Dringenberg, HC
de Souza-Silva, MA
Schwarting, RKW
Huston, JP
机构
[1] Univ Dusseldorf, Inst Physiol Phychol 1, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Ctr Biol & Med Res, D-40225 Dusseldorf, Germany
[3] Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada
关键词
dopamine; histamine; H1 receptor antagonists; neostriatum; nucleus accumbens; microdialysis;
D O I
10.1007/PL00005274
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dopaminergic system plays a central role in the processing of reward or reinforcement since drugs that have reinforcing properties all share the ability to elevate dopamine (DA) levels in the nucleus accumbens or neostriatum. Histamine H1 receptor antagonists are known to have reinforcing effects in humans and laboratory rats. Here, we examined the effect of systemic (i.p.) treatment with two H1 antagonists, chlorpheniramine and pyrilamine, on the extracellular levels of DA and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the neostriatum and nucleus accumbens of urethane-anesthetized rats. Dopamine and metabolites were measured using in vivo microdialysis and HPLC with electrochemical detection. Saline injections did not produce significant effects on DA, DOPAC, or HVA levels in the neostriatum or nucleus accumbens. In the neostriatum, chlorpheniramine administration (5 and 20 mg/kg) produced a sustained increase in DA to approximately 140 and 180% of pre-injection baseline levels, respectively. In the nucleus accumbens, chlorpheniramine (20 mg/kg) produced a transient increase in DA levels to about 300% of baseline. In both the neostriatum and nucleus accumbens, DOPAC and HVA decreased after chlorpheniramine treatment. Pyrilamine administration (10 and 20 mg/kg) produced a sustained increase in neostriatal DA levels to 140 and 165%, respectively, and accumbens DA increased transiently to 230% after a dose of 20 mg/kg. Levels of neostriatal and accumbens DOPAC and HVA decreased after pyrilamine treatment. These results show that H1 antagonists can potently enhance DA levels in the neostriatum and nucleus accumbens of urethane-anesthetized rats. The neurochemical effects on DA and its metabolites seen here (increased DA, decreased DOPAC and HVA) are similar to those commonly observed with drugs of abuse (e.g. psychostimulants). The interaction of H1 antagonists with dopaminergic transmission may explain the reinforcing effects and abuse potential associated with these compounds.
引用
收藏
页码:423 / 429
页数:7
相关论文
共 50 条
  • [21] Effects of nimodipine on extracellular dopamine levels in the rat nucleus accumbens in ethanol withdrawal
    Rossetti, ZL
    Isola, D
    De Vry, J
    Fadda, F
    NEUROPHARMACOLOGY, 1999, 38 (09) : 1361 - 1369
  • [22] Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats
    Murillo-Rodriguez, Eric
    Haro, Reyes
    Palomero-Rivero, Marcela
    Millan-Aldaco, Diana
    Drucker-Colin, Rene
    BEHAVIOURAL BRAIN RESEARCH, 2007, 176 (02) : 353 - 357
  • [23] Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo
    Taber, MT
    Baker, GB
    Fibiger, HC
    SYNAPSE, 1996, 24 (02) : 165 - 172
  • [24] Role of protein kinase Cα in signaling from the histamine H1 receptor to the nucleus
    Megson, AC
    Walker, EM
    Hill, SJ
    MOLECULAR PHARMACOLOGY, 2001, 59 (05) : 1012 - 1021
  • [25] Deltorphin II enhances extracellular levels of dopamine in the nucleus accumbens via opioid receptor-independent mechanisms
    Murakawa, K
    Hirose, N
    Takada, K
    Suzuki, T
    Nagase, H
    Cools, AR
    Koshikawa, N
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 491 (01) : 31 - 36
  • [26] HISTAMINE H1 RECEPTOR IS REQUIRED FOR ATHEROGENESIS
    Rozenberg, I.
    Akhmedov, A.
    Kouroedov, A.
    Mocharla, P.
    Watanabe, T.
    Boren, J.
    Odermatt, B.
    Luescher, T. F.
    Tanner, F. C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 1 - 2
  • [27] Histamine H1 Receptor is Required for Atherogenesis
    Rozenberg, Izabela
    Mocharla, Pavani
    Becher, Burkhard
    Hofmann, Janin
    Akhmedov, Alexander
    Boren, Jan
    Luescher, Thomas F.
    Tanner, Felix C.
    CIRCULATION, 2008, 118 (18) : S410 - S411
  • [28] Expression of histamine H1 receptor in placenta
    K. Matsuyama
    N. Kawakami
    T. Ichikawa
    Y. Nitta
    K. Ishimura
    S. Horio
    H. Fukui
    Inflammation Research, 2004, 53 : S85 - S86
  • [29] CONSTITUTIVE ACTIVITY OF THE HISTAMINE H1 RECEPTOR
    Nijmeijer, Saskia
    Leurs, Rob
    Vischer, Henry F.
    METHODS IN ENZYMOLOGY, VOLUME 484: CONSTITUTIVE ACTIVITY IN RECEPTORS AND OTHER PROTEINS, PART A, 2010, 484 : 127 - 147
  • [30] Structure of the human Histamine H1 receptor
    Weyand, Simone
    Shimamura, Tatsuro
    Shiroishi, Mitsunori
    Tsujimoto, Hirokazu
    Winter, Graeme
    Katritch, Vsevolod
    Abagyan, Ruben
    Cherezov, Vadim
    Liu, Wei
    Han, Gye Won
    Kobayashi, Takuya
    Stevens, Raymond C.
    Iwata, So
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2012, 68 : S29 - S29